Additionally, patients with systemic sclerosis experienced significant improvement in heart, joint, and skin manifestations, reinforcing the critical role of B-cell–mediated autoimmunity in these diseases and suggesting broader therapeutic potential for CD19 CAR T-cell therapy (14). This evidence concerns the gene CD19 and systemic sclerosis.